• School of Medicine ›

Jill Elaine Wykosky, PhD

Post-doctoral Fellow
Section of Human Carcinogenesis
Laboratory of Tumor Biology
Ludwig Institute for Cancer Research 
La Jolla, CA 

Email:jwykosky@ucsd.edu

Education:

Ph.D., Molecular Medicine, 2003 -2008
Wake Forest University
School of Medicine
Winston-Salem, NC

Areas of specialization: Cancer Biology, Brain Tumor Biology

B.S., Microbiology with Honors in Biological Sciences, 1999-2003, Summa cum Laude
Related area, Chemistry
University of Pittsburgh, Pittsburgh, Pennsylvania,

Certified, Conceptual Foundations of Medicine

Research Interests:

The oncogenic role of signal transduction mediated by protein or lipid phosphatases as well as the differences between the signaling effected by oncogenic mutant receptors and their normal wild-type counterparts.

Publications:

Wykosky J and Debinski W. Molecular Targeting of IL-13R2 and EphA2 Receptor in GBM. In: E.G. Van Meir (Ed.) CNS Cancer: Models, Prognostic Factors, and Targets. Dec 2008. Springer.

Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, and Debinski W. Soluble, monomeric ephrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene, advance online publication, 15 September 2008.

Wykosky J and Debinski W. Function and therapeutic targeting of the EphA2/ephrinA1 system in solid tumors. Molecular Cancer Research, 2008, In press.

Wykosky J, Gibo DM, Stanton C, and Debinski W. IL-13 Receptor alpha 2, EphA2, and Fra-1 as molecular denominators of high-grade astrocytomas. Clinical Cancer Research 14(1), 199-208, 2008.

Wykosky J, Gibo DM, and Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. MolecularCancer Therapeutics 6(12): 3208-3218, 2007.

For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine.

Grants:

NRSA Pre-doctoral fellowship: NINDS, 2006-2008
F31 NSO55533-01 “EphA2: Function and Targeting in Malignant Gliomas”